SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

FSD Pharma Inc. – ‘6-K’ for 11/7/23

On:  Tuesday, 11/7/23, at 10:34am ET   ·   For:  11/7/23   ·   Accession #:  1654954-23-13851   ·   File #:  1-39152

Previous ‘6-K’:  ‘6-K’ on 11/7/23 for 11/6/23   ·   Next:  ‘6-K’ on 11/15/23 for 9/30/23   ·   Latest:  ‘6-K’ on 5/7/24 for 5/6/24   ·   2 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/07/23  FSD Pharma Inc.                   6-K        11/07/23    3:61K                                    Blueprint/FA

Current, Quarterly or Annual Report by a Foreign Issuer   —   Form 6-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML     13K 
                Issuer                                                           
 2: EX-99.1     Material Change Report                              HTML     29K 
 3: EX-99.2     Material Change Report                              HTML     11K

‘6-K’   —   Current, Quarterly or Annual Report by a Foreign Issuer

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 C: 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

 

FORM 6-K

_________________________

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2023

 

Commission File Number: 001-39152

_________________________

 

FSD PHARMA INC.

(Registrant)

_________________________

 

199 Bay St., Suite 4000

Toronto, Ontario M5L 1A9 Canada

(Address of Principal Executive Offices)

_________________________

 

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

FSD PHARMA INC.

 

(Registrant)

 

 

Date November 6, 2023

By

/s/ Nathan Coyle

 

Nathan Coyle

 

Chief Financial Officer

 

 

 
2

 

 

EXHIBIT INDEX

 

Exhibit

 

Description of Exhibit

99.1

 

Material Change Report dated October 13, 2023

 

 

 

99.2

 

Material Change Report dated November 2, 2023  

 

 
3

 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘6-K’ Filing    Date    Other Filings
Filed on / For Period end:11/7/236-K
11/6/236-K
 List all Filings 

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/20/24  FSD Pharma Inc.                   424B5       2/16/24    1:863K                                   RDG Filings/FA
12/26/23  FSD Pharma Inc.                   F-3        12/22/23    5:33M                                    Blueprint/FA
↑Top
Filing Submission 0001654954-23-013851   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 14, 3:09:53.2am ET